Michael Wilhelm is a seasoned leader in the biotech industry, having served as a strategic business development executive with extensive expertise in areas such as pipeline development, investor relations, and strategic relationships. Currently, he is the President and CEO of New Amsterdam Sciences, Inc., where he has steered continuous growth and operational efficiencies, raising $50M in investments. Before this, he served as Director of Strategic Partnering and Public Relations, growing corporate sponsorships and developing essential partnerships. He has also been a Founder, Managing Director, and Principal at Foresight Capital Corporation since 1996, overseeing private equity and debt funding exceeding $100M. Earlier, as the CEO and Chairman of ImmuneRegen BioSciences Holdings, Inc., Wilhelm secured over $100M in initial capital, facilitating significant business strategies and relationships in the sector.